In contrast, NSCLC patients harboring mutations of epidermal growth factor receptor (EGFR) and/or anaplastic lymphoma kinase (ALK) might not benefit from ICIs treatment (Gainor et al. 2016; Haratani et al. 2017). Here, ALK is linked to non-small cell lung carcinoma.